Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) has notified the stock exchanges of an upcoming board meeting, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 6, 2026, and signed by Company Secretary & Compliance Officer Sisir K. Mishra.

Board Meeting Details

The following key details have been disclosed regarding the scheduled board meeting:

Agenda and Compliance

The board meeting has been convened, inter alia, to consider and approve the Audited Financial Results of the company — both Standalone and Consolidated — for the quarter and financial year ended March 31, 2026. The intimation was made in accordance with applicable SEBI listing regulations, underscoring the company's commitment to regulatory compliance and timely disclosure.

Trading Window Closure

In continuation of the company's earlier communication dated March 27, 2026 regarding the closure of the Trading Window, designated persons and their immediate relatives are restricted from dealing in the shares of the company. The Trading Window shall remain closed until May 14, 2026, two days after the scheduled board meeting date.

Company Background

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, is headquartered at Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana, with its registered office located in Andheri East, Mumbai, Maharashtra.

Cohance Lifesciences Limited announced a significant leadership transition following its Board meeting. The company has appointed Umang Vohra, former CEO of Cipla Limited, as Executive Chairman effective May 1, and Group Chief Executive Officer effective May 20.

Leadership Transition Details

The Board accepted the resignation of Mr. Vivek Sharma as Executive Chairman and Director of the Company, effective from the close of business hours on April 30. Mr. Sharma tendered his resignation due to personal reasons. Following his resignation, Mr. Sharma will continue to provide services to the Company in the role of Special Advisor for a period of nine months to help transition the business effectively.

Strategic Leadership Appointment

The appointment of Mr. Vohra reflects a deliberate, strategic decision by the Board to bring in a leader whose profile is specifically suited to the company's transformation and next phase of growth. Mr. Vohra is one of the most accomplished leaders in the pharmaceutical industry with a career spanning more than three decades. As former CEO and Managing Director of Cipla Limited, he led the company's transformation over the last decade to build a diversified global pharmaceutical enterprise.

Mr. Vohra commented on his appointment: "I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation."

Employee Stock Option Plan

The Board approved the adoption of the Cohance Lifesciences Limited – Employee Stock Option Plan in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations. The plan covers 25,918,613 employee stock options, each convertible into one equity share of face value INR 1.00 each, representing 6.25% of the fully diluted equity share capital.

The exercise price per option shall not be less than INR 325.00 per share, which represents a 2.50% discount to the average market price over the last 21 trading days prior to the Board's approval. The Company will restrict outstanding grants under the existing ESOP to not more than 1.50% of share capital on a fully diluted basis.

Company Platform and Future Direction

Cohance Lifesciences has built a differentiated position in the global CDMO landscape through its depth in proprietary chemistry, complex multi-step synthesis, and advanced process R&D. The company's capabilities span complex APIs, ADCs and Oligonucleotides, complex intermediates, performance materials and specialty ingredients. With integrated R&D centres, over 400 R&D scientists, and established partnerships with global pharmaceutical innovators, the platform is anchored in science.

Pankaj Patwari, Managing Director at Advent, stated: "The platform will greatly benefit from a leader like Umang, who brings an owner-manager mindset, and who can build on the business's scientific foundation, drive commercial scale, deepen customer partnerships, and develop a leading operating culture."